Literature DB >> 9055795

Locomotor deficits induced by experimental spinal cord demyelination are abolished by spontaneous remyelination.

N D Jeffery1, W F Blakemore.   

Abstract

Demyelinating lesions induced by intraspinal injection of gliotoxin have been studied for many years in order to gain insights into reasons for failure of remyelination and to improve understanding of the axonal conduction disorders in multiple sclerosis. Although the electrophysiological correlates of experimental demyelination and remyelination are well established, the behavioural effects have not been investigated. In this study we aimed to determine whether behavioural deficits could be detected during spinal cord demyelination, and furthermore, whether remyelination was associated with return of lost function. We used injections of the gliotoxin ethidium bromide into the dorsal funiculus of the cervical spinal cord of the rat to induce zones of demyelination and compared the effects on locomotion with those resulting from saline injections. The resulting locomotor deficits were quantified by analysis of foot placement during traverse of a horizontal 18 mm diameter wooden beam. Following ethidium bromide injection there was a decrease in security of foot placement, that recovered by approximately 5 weeks post-injection. In a second experiment, remyelination was prevented by exposure of the spinal cord to 40 Gy of X-irradiation. Behavioural deficits were induced as before, but the animals failed to recover throughout the duration of the experiment. Saline-injected animals in both experiments exhibited minimal deficits and quickly recovered. We conclude that demyelination produces detectable behavioural deficits which disappear following spontaneous remyelination.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9055795     DOI: 10.1093/brain/120.1.27

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  54 in total

Review 1.  Stem cell transplantation in multiple sclerosis: current status and future prospects.

Authors:  Gianvito Martino; Robin J M Franklin; Anne Baron Van Evercooren; Douglas A Kerr
Journal:  Nat Rev Neurol       Date:  2010-04-20       Impact factor: 42.937

Review 2.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

3.  Imaging of CNS myelin by positron-emission tomography.

Authors:  Bruno Stankoff; Yanming Wang; Michel Bottlaender; Marie-Stephane Aigrot; Frederic Dolle; Chunying Wu; Douglas Feinstein; Guo-Feng Huang; Frank Semah; Chester A Mathis; William Klunk; Robert M Gould; Catherine Lubetzki; Bernard Zalc
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

Review 4.  Oligodendrocyte fate after spinal cord injury.

Authors:  Akshata Almad; F Rezan Sahinkaya; Dana M McTigue
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

5.  Oncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelination.

Authors:  Evelien Houben; Kris Janssens; Doryssa Hermans; Jennifer Vandooren; Chris Van den Haute; Melissa Schepers; Tim Vanmierlo; Ivo Lambrichts; Jack van Horssen; Veerle Baekelandt; Ghislain Opdenakker; Wia Baron; Bieke Broux; Helena Slaets; Niels Hellings
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-18       Impact factor: 11.205

6.  New developments in the treatment of optic neuritis.

Authors:  Thomas M Jenkins; Ahmed T Toosy
Journal:  Eye Brain       Date:  2010-06-17

7.  Translational control of myelin basic protein expression by ERK2 MAP kinase regulates timely remyelination in the adult brain.

Authors:  Kelly Michel; Tianna Zhao; Molly Karl; Katherine Lewis; Sharyl L Fyffe-Maricich
Journal:  J Neurosci       Date:  2015-05-20       Impact factor: 6.167

8.  Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis.

Authors:  P D Murray; D B McGavern; S Sathornsumetee; M Rodriguez
Journal:  Brain       Date:  2001-07       Impact factor: 13.501

Review 9.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

10.  Cervical spinal demyelination with ethidium bromide impairs respiratory (phrenic) activity and forelimb motor behavior in rats.

Authors:  N L Nichols; A M Punzo; I D Duncan; G S Mitchell; R A Johnson
Journal:  Neuroscience       Date:  2012-11-14       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.